The promise of macrophage directed checkpoint inhibitors in myeloid malignancies

Kruger, 2019, Advances in cancer immunotherapy 2019 - latest trends, J Exp Clin Canc Res, 38, 268, 10.1186/s13046-019-1266-0 Buchbinder, 2016, CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition, Am J Clin Oncol, 39, 98, 10.1097/COC.0000000000000239 Chao, 2019, Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies, Front Oncol, 9, 1380, 10.3389/fonc.2019.01380 Mantovani, 2017, Tumour-associated macrophages as treatment targets in oncology, Nat Rev Clin Oncol, 14, 399, 10.1038/nrclinonc.2016.217 Mantovani, 2018, Macrophage checkpoint blockade in cancer - back to the future, N Engl J Med, 379, 1777, 10.1056/NEJMe1811699 Borate, 2019, Phase ib study of the anti-TIM-3 antibody MBG453 in combination with decitabine in patients with high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), Blood, 134, 570, 10.1182/blood-2019-128178 Chao, 2012, The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications, Curr Opin Immunol, 24, 225, 10.1016/j.coi.2012.01.010 McCracken, 2015, Molecular pathways: activating T cells after cancer cell phagocytosis from blockade of CD47 "don't eat me" signals, Clin Canc Res, 21, 3597, 10.1158/1078-0432.CCR-14-2520 Majeti, 2009, CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells, Cell, 138, 286, 10.1016/j.cell.2009.05.045 Kim, 2012, Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells, Leukemia, 26, 2538, 10.1038/leu.2012.141 Advani, 2019, CD47 blockade and rituximab in non-hodgkin's lymphoma, N Engl J Med, 380, 497 Willingham, 2012, The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors, Proc Natl Acad Sci U S A, 109, 6662, 10.1073/pnas.1121623109 Edris, 2012, Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma, Proc Natl Acad Sci U S A, 109, 6656, 10.1073/pnas.1121629109 Jiang, 2013, CD47 is expressed abnormally on hematopoietic cells in myelodysplastic syndrome, Leuk Res, 37, 907, 10.1016/j.leukres.2013.04.008 Pang, 2013, Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes, Proc Natl Acad Sci U S A, 110, 3011, 10.1073/pnas.1222861110 Chao, 2010, Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47, Sci Transl Med, 2, 63ra94, 10.1126/scitranslmed.3001375 Barth, 2017, The "phagocytic synapse" and clearance of apoptotic cells, Front Immunol, 8, 1708, 10.3389/fimmu.2017.01708 He, 2019, Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis, Nat Commun, 10, 533, 10.1038/s41467-018-08013-z Boasman, 2019, CALR and CD47: an insight into their roles in the disease progression of MDS and MPN, J Blood Disord Transfus, 10, 10.4172/2155-9864.1000413 Feng, 2018, Combination treatment with 5F9 and azacitidine enhances phagocytic elimination of acute myeloid leukemia, Blood, 132, 2729, 10.1182/blood-2018-99-120170 Zeidan, 2019, A phase I study of CC-90002, a monoclonal antibody targeting CD47, in patients with relapsed and/or refractory (R/R) acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS): final results, Blood, 134, 1320, 10.1182/blood-2019-125363 Vyas, 2018, Initial phase 1 results OF the first-in-class ANTI-CD47 antibody HU5F9-G4 Sallman, 2020, Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: phase Ib results, J Clin Oncol, 38, 7507, 10.1200/JCO.2020.38.15_suppl.7507 DiNardo, 2019, Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia, Blood, 133, 7, 10.1182/blood-2018-08-868752 DiNardo, 2020, Azacitidine and venetoclax in previously untreated acute myeloid leukemia, N Engl J Med, 383, 617, 10.1056/NEJMoa2012971 Oldenborg, 2000, Role of CD47 as a marker of self on red blood cells, Science, 288, 2051, 10.1126/science.288.5473.2051 Chen, 2018, RBC-specific CD47 pruning confers protection and underlies the transient anemia in patients treated with anti-CD47 antibody 5F9, Blood, 132, 2327, 10.1182/blood-2018-99-115674 Ansell, 2016, A phase 1 study of TTI-621, a novel immune checkpoint inhibitor targeting CD47, in patients with relapsed or refractory hematologic malignancies, Blood, 128, 1812, 10.1182/blood.V128.22.1812.1812 Boyd-Kirkup, 2017, HMBD004, a novel anti-CD47xCD33 bispecific antibody displays potent anti-tumor effects in pre-clinical models of AML, Blood, 130 Golubovskaya, 2017, CD47-CAR-T cells effectively kill target cancer cells and block pancreatic tumor growth, Cancers (Basel), 9 Morrissey, 2018, Chimeric antigen receptors that trigger phagocytosis, Elife, 7, 10.7554/eLife.36688 Valentin, 2018, The fully human anti-CD47 antibody SRF231 has dual-mechanism antitumor activity against chronic lymphocytic leukemia (CLL) cells and increases the activity of both rituximab and venetoclax, Blood, 132, 4393, 10.1182/blood-2018-99-110181 Tseng, 2013, Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response, Proc Natl Acad Sci U S A, 110, 11103, 10.1073/pnas.1305569110 Soto-Pantoja, 2014, CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy, Canc Res, 74, 6771, 10.1158/0008-5472.CAN-14-0037-T Sallman, 2020, TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype, Blood, 10.1182/blood.2020006158 Williams, 2019, The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia, Cancer, 125, 1470, 10.1002/cncr.31896 Chao, 2010, Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma, Cell, 142, 699, 10.1016/j.cell.2010.07.044 Advani, 2018, CD47 blockade by Hu5F9-G4 and rituximab in non-hodgkin's lymphoma, N Engl J Med, 379, 1711, 10.1056/NEJMoa1807315 Zhang, 2018, APR-246 reactivates mutant p53 by targeting cysteines 124 and 277, Cell Death Dis, 9, 439, 10.1038/s41419-018-0463-7 Sallman, 2019, Phase 2 results of APR-246 and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia (AML), Blood, 134, 676, 10.1182/blood-2019-131055 Cluzeau, 2019, APR-246 combined with azacitidine (AZA) in TP53 mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). A phase 2 study by the groupe francophone des myélodysplasies (GFM), Blood, 134, 677, 10.1182/blood-2019-125579 Kuykendall, 2018, Acute myeloid leukemia: the good, the bad, and the ugly, Am Soc Clin Oncol Educ Book, 38, 555, 10.1200/EDBK_199519 Hunter, 2019, Current status and new treatment approaches in TP53 mutated AML, Best Pract Res Clin Haematol, 32, 134, 10.1016/j.beha.2019.05.004